After treatment of the imatinib mesylate (IM)-sensitive CML cell line KCL22S with Dasatinib or Nilotinib, a restoration of KMT2C gene expression and a higher rate of apoptosis and enhanced expression of p21 (CDKN1A) compared to the control group was observed, accompanied by a decrease in the expression of CDK2, CDK4, and Cyclin B1 (CCNB1), which suggests that the p53 regulatory pathway is involved in the regulation of cancer by KMT2C (49). The gene discussed is CDKN1A; the disease is cancer.